News
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound.
"Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound.
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...
Lilly Expands Zepbound Access via LillyDirect: All approved single-dose vial strengths of Zepbound (tirzepatide), including 12.5 mg and 15 mg, are now available for $499 per month through ...
"Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound. In the meantime, the availability of the two ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results